Paid Clinical Trials Colorado
Discover 1,628 paid clinical trials in Colorado. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Sponsor:
Amgen
Location:
Code:
NCT05325866
Conditions
Solid Tumors
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Bemarituzumab
A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Sponsor:
Cytokinetics
Location:
Code:
NCT06412666
Conditions
Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Aficamten
Placebo
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04616326
Conditions
Chronic Migraine
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Galcanezumab
Placebo
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Sponsor:
VistaGen Therapeutics, Inc.
Location:
Code:
NCT06615557
Conditions
Social Anxiety Disorder (SAD)
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Fasedienol Nasal Spray
Placebo Nasal Spray
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Sponsor:
C4 Therapeutics, Inc.
Location:
Code:
NCT04756726
Conditions
Multiple Myeloma
Lymphoma, Non-Hodgkin's
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemsidomide
Dexamethasone Oral
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Sponsor:
Icahn School of Medicine at Mount Sinai
Location:
Code:
NCT04045665
Conditions
Atrial Fibrillation
Stroke
Bleeding
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Antiplatelet-only strategy
Oral Anticoagulant plus background antiplatelet therapy
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Sponsor:
North Texas Veterans Healthcare System
Location:
Code:
NCT02660866
Conditions
Peripheral Arterial Disease
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo + background APT + SMT
Vorapaxar 2.08 mg/d + background APT + SMT.